Responses
Regular and Young Investigator Award Abstracts
Cell Therapies
275 Manufacture of allogeneic, HLA-matched, TCR-edited T-cell therapy reactive against minor histocompatibility antigen 1 to treat acute myeloid leukemia in combination with CD34 HSCT with the potential for high potency and durability
Compose a Response to This Article
Other responses
No responses have been published for this article.